Bank of New York Mellon Corp Acquires 221,957 Shares of SELLAS Life Sciences Group, Inc. $SLS

Key Points

• Bank of New York Mellon increased its SELLAS Life Sciences Group stake by 86.6%, acquiring 221,957 additional shares for a total of 478,366 shares valued at approximately $2.02 million.
• Other institutional investors also expanded or initiated positions, with institutional ownership reaching 17.38% of SLS shares.
• Analyst sentiment is mixed: two analysts rate the stock Buy and one rates it Sell, resulting in an overall Hold rating and an average price target of $10.00; SLS recently traded at $12.01.

Bank of New York Mellon Corp boosted its holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 86.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 478,366 shares of the company's stock after buying an additional 221,957 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.26% of SELLAS Life Sciences Group worth $2,023,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of SLS. Fifth Third Bancorp bought a new position in shares of SELLAS Life Sciences Group in the 1st quarter valued at $253,000. Dagco Inc. grew its position in SELLAS Life Sciences Group by 78.1% during the 1st quarter. Dagco Inc. now owns 1,028,780 shares of the company's stock worth $4,352,000 after acquiring an additional 451,240 shares during the last quarter. World Investment Advisors bought a new position in SELLAS Life Sciences Group in the fourth quarter valued at about $166,000. Axxcess Wealth Management LLC raised its position in SELLAS Life Sciences Group by 121.1% in the fourth quarter. Axxcess Wealth Management LLC now owns 35,370 shares of the company's stock valued at $133,000 after purchasing an additional 19,370 shares during the last quarter. Finally, Millington Financial Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group during the fourth quarter valued at about $93,000. Institutional investors and hedge funds own 17.38% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Alliance Global Partners reissued a "buy" rating on shares of SELLAS Life Sciences Group in a report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, SELLAS Life Sciences Group presently has an average rating of "Hold" and an average target price of $10.00.

SELLAS Life Sciences Group Stock Performance

NASDAQ SLS opened at $12.01 on Monday. The firm has a market capitalization of $2.36 billion, a PE ratio of -52.22 and a beta of 2.48. The business's 50-day moving average price is $10.92 and its two-hundred day moving average price is $7.15. SELLAS Life Sciences Group, Inc. has a 12 month low of $1.39 and a 12 month high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

Want to see what other hedge funds are holding SLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source